Wandercraft Buys Ekso Bionics, Bringing Four Medical Exoskeletons Under One Owner

Four robotic devices designed to help people stand and walk now share one owner. Wandercraft acquired Ekso Bionics from a subsidiary of ChronoScale Holdings on October 1, 2026, combining rehabilitation equipment with personal-use exoskeletons. Wandercraft says it intends to keep supporting all four products—and the clinicians, customers and individuals who depend on them.

The transaction is complete, not an agreement awaiting closing. Wandercraft and ChronoScale’s boards unanimously approved it, and signing and closing happened simultaneously. Financial terms were not disclosed. The announcement pairs a change in ownership with commitments on product support, clinical services and access to personal mobility devices.

Two rehabilitation platforms, a shared clinical network

In rehabilitation, the combination joins Wandercraft’s Atalante X with EksoNR. The companies say the two platforms already support patients in standing and walking at more than 700 rehabilitation centers worldwide. That figure describes their combined clinical footprint, rather than new installations resulting from the acquisition.

Together, the platforms hold U.S. Food and Drug Administration clearances and European CE marking covering stroke, spinal cord injury, multiple sclerosis and acquired brain injury, according to the announcement. Those authorizations are described across the combined platforms; they are not presented as identical approvals for every device. The companies also say rehabilitation centers can now consult specialists familiar with both systems while retaining dedicated, product-specific support.

Different approaches to mobility at home

01Hands-free, self-balancing

Eve

Wandercraft describes Eve as bringing its hands-free, self-balancing technology into the home for eligible individuals with spinal cord injuries.

02Modular wearable exoskeleton

Indego Personal

Indego Personal offers a modular wearable approach to upright mobility for eligible individuals with spinal cord injuries.

The personal-use products serve the same stated patient group but offer different designs. Wandercraft describes them as options that can be matched to individual needs and goals. Its commitment is to support both, alongside the two rehabilitation platforms—not to replace the portfolio with a single device. For existing users, continued support is the clearest product-level promise attached to the purchase.

European reach meets a U.S. clinical base

Wandercraft frames the businesses as geographically complementary. It brings robotics and physical-AI expertise, along with what it describes as leadership in Europe, the Middle East and Africa. Ekso contributes a strong U.S. presence, clinical experience and commercial reach. The rationale rests on combining technologies, teams and relationships on both sides of the Atlantic.

CEO and co-founder Matthieu Masselin says bringing those assets together creates an opportunity to reach more patients and rehabilitation professionals worldwide. That is an expansion goal, not a measured outcome of the deal. The operational change the companies identify is a broader international service network drawing on shared clinical expertise, while keeping support tied to each product.

Access involves training and payment, too

Wandercraft’s access work extends beyond the devices themselves. Patients are already receiving training at its Walk in New York rehabilitation center. A dedicated team helps users and care teams handle benefits, documentation, reimbursement, financing and coordination with clinicians and payers. The acquisition announcement highlights that infrastructure as part of its approach to deploying personal exoskeletons.

The announcement says Medicare covers qualifying personal exoskeletons under its brace benefit for U.S. individuals who meet eligibility and medical-necessity requirements. Billing uses HCPCS code K1007, the reimbursement identifier cited by the company. This is conditional coverage, not a blanket entitlement for everyone with a spinal cord injury.

The combined company says it will advocate for broader coverage worldwide. That leaves a distinction between what the deal delivers now and what it seeks next: ownership and support commitments are in place, while wider reimbursement remains an ambition.